ArticleScientific reports2019
PolyBall: A new adsorbent for the efficient removal of endotoxin from biopharmaceuticals.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Host Response Impairs Tissue Integration of a Fibrin Hydrogel Scaffold Containing Poly(ε-caprolactone) Nanofibers for Peripheral Nerve Repair.Biomimetics (Basel, Switzerland) · 2026Article
- Upstream endotoxin removal in recombinant protein purification: an optimised pre-cell disruption strategy for reducing endotoxin contamination of inclusion bodies in Escherichia coli.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Architects of folding, editors of immunity: the strategic use ofFrontiers in immunology · 2026Article
- Cost-Effective and High-Throughput LPS Detection via Microdroplet Technology in Biopharmaceuticals.Biosensors · 2025Article
- Generation of Endotoxin-Specific Monoclonal Antibodies by Phage and Yeast Display for Capturing Endotoxin.International journal of molecular sciences · 2024Article
- A simple and effective method to remove pigments from heterologous secretory proteins expressed in Pichia pastoris.Advanced biotechnology · 2024Article
- Recovering What Matters: High Protein Recovery after Endotoxin Removal from LPS-Contaminated Formulations Using Novel Anti-Lipid A Antibody Microparticle Conjugates.International journal of molecular sciences · 2023Article
- Recombinant vaccines in 2022: a perspective from the cell factory.Microbial cell factories · 2022Review
- Plant produced endotoxin binding recombinant proteins effectively remove endotoxins from protein samples.Scientific reports · 2022Article
- Development and Characterization of Silver-Doped Multi-Walled Carbon Nanotube Membranes for Water Purification Applications.Membranes · 2022Article
- Sustainable Packaging Material Based on PCL Nanofibers andPolymers · 2022Article
- Effect of pH-Regulation on the Capture of Lipopolysaccharides fromMaterials (Basel, Switzerland) · 2021Article
- Advances in the Development of Biomaterials for Endotoxin Adsorption in Sepsis.Frontiers in bioengineering and biotechnology · 2021Review
- Characterisation of aptamer-anchored poly(EDMA-co-GMA) monolith for high throughput affinity binding.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of endotoxin, also known as lipopolysaccharides (LPS), as a side product appears to be a major drawback for the production of certain biomolecules that are essential for research, pharmaceutical, and industrial applications. In the biotechnology industry, gram-negative bacteria (e.g., Escherichia coli) are widely used to produce recombinant products such as proteins, plasmid DNAs and vaccines. These products are contaminated with LPS, which may cause side effects when administered to animals or humans. Purification of LPS often suffers from product loss. For this reason, special attention must be paid when purifying proteins aiming a product as free as possible of LPS with high product recovery. Although there are a number of methods for removing LPS, the question about how LPS removal can be carried out in an efficient and economical way is still one of the most intriguing issues and has no satisfactory solution yet. In this work, polymeric poly-ε-caprolactone (PCL) nanoparticles (NPs) (d
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.